TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells

Yoshikane Kikushige, Toshihiro Miyamoto

研究成果: ジャーナルへの寄稿学術誌査読

53 被引用数 (Scopus)

抄録

Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), which represent the ultimate therapeutic target for AML. Recent studies have identified several AML LSC-specific surface antigens as candidate targets of therapeutic molecules. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, with the exception of acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In xenograft models reconstituted with human AML LSCs or HSCs, an anti-human TIM-3 mouse IgG2a antibody with cytotoxic activities eradicates AML LSCs in vivo, but does not affect normal human hematopoiesis. Thus, TIM-3 is a promising therapeutic target for the eradication of AML LSCs.

本文言語英語
ページ(範囲)627-633
ページ数7
ジャーナルInternational journal of hematology
98
6
DOI
出版ステータス出版済み - 12月 2013

!!!All Science Journal Classification (ASJC) codes

  • 血液学

フィンガープリント

「TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル